Notice of Special Interest (NOSI): Administrative supplements to active NIH awards to support replication studies using independent contract resources (NOT-RM-24-013)

Sponsor: NIH Office of Strategic Coordination (Common Fund)

Award: The supplement budget request must reflect the actual needs of the proposed one-year project and are limited to $50,000 direct cost per project.

Due Date: November 15, 2024.

Human Brain Single-cell Genomics Explorer (U24 - Clinical Trial Not Allowed) (RFA-NS-24-038)

Sponsor: National Institutes of Health

Award: Annual direct costs may not exceed $1M. The maximum project duration for this Pilot Project is 3 years.

Due Date: Letter of Intent due January 14, 2025. Application due February 14, 2025.

Notice of Information: Technical Assistance Webinars for RFA-NS-25-024 Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NOT-NS-25-003)

Sponsor: National Institute of Neurological Disorders and Stroke

Award: Pre-application, technical assistance webinar for RFA-NS-25-024– Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required).

Due Date: Tuesday, October 29, 2024 from 1:30 PM – 2:30 PM (Eastern Time) and Tuesday, December 3, 2024 from 2 PM – 3 PM (Eastern Time)

Notice of Special Interest (NOSI): Ruth L. Kirschstein NRSA Fellowship Awards to Support Training in Research Related to Down Syndrome as Part of the INCLUDE Project (NOT-OD-24-143)

Sponsor: National Institutes of Health

Due Date: This notice applies to due dates on or after December 8, 2024 and subsequent receipt dates through September 8, 2027.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) (PAR-25-055)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Centers on the Demography and Economics of Aging, Including Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (D&E Centers) (P30 Clinical Trial Optional) (RFA-AG-25-007)

Sponsor: National Institute on Aging

Due Date: Letter of Intent due October 1, 2024. Application due November 01, 2024.

Centers on the Demography and Economics of Aging and Alzheimers Disease and Alzheimers Disease-Related Dementias Coordinating Center (U24 Clinical Trial Optional) (RFA-AG-25-008)

Sponsor: National Institute on Aging

Due Date: Letter of Intent due October 1, 2024. Application due November 01, 2024.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) (PAR-24-294)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) (PAR-25-050)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Multiple due dates; see announcement.

Notice of Special Interest (NOSI): The Role of the Immune System in Aging Brain and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (NOT-AG-24-010)

Sponsor: National Institute on Aging, National Institute of Allergy and Infectious Diseases

Award: This initiative relates to the following notices of funding opportunities (NOFOs): PAR-22-093 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional); PAR-22-094 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional).

Due Date: This notice applies to due dates on or after November 12, 2024 and subsequent receipt dates through December 31, 2027.

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) (PA-25-080)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-24-293)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) (RFA-NS-25-018)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (RFA-NS-25-024)

Sponsor: National Institute of Neurological Disorders and Stroke

Due Date: Application due January 24, 2025. Letter of intent due 30 days prior to application.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) (PAR-25-051)

Sponsor: National Institutes of Health

Due Date: Multiple due dates; see announcement.